Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

被引:113
作者
Doll, JA
Reiher, FK
Crawford, SE
Pins, MR
Campbell, SC
Bouck, NP
机构
[1] Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA
[3] Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA
[4] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
关键词
prostate cancer; benign prostatic hyperplasia; neovascularization; antiangiogenesis; prostate stroma;
D O I
10.1002/pros.10025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate cells secrete many molecules capable of regulating angiogenesis; however, which of these actually function as essential regulators of neovascularization is not yet clear. METHODS. Functional angiogenic mediators secreted by normal and diseased prostate cells were identified using an in vitro angiogenesis assay. These factors were quantified by immunoblot or ELISA and localized in tissue by immunohistochemistry. RESULTS. Normal prostate epithelial cell secretions were anti-angiogenic due to inhibitory thrombospondin-1 (TSP-1) whereas this inhibitor was decreased in the pro-angiogenic secretions derived from benign prostatic hyperplasia (BPH) and cancer cells. This proangiogenic activity depended primarily on fibroblast growth factor-2 (FGF-2) and/or vascular endothelial growth factor (VEGF) whose secretion was increased. Immunolocalization studies confirmed that the changes detected in vitro also occurred in vivo. CONCLUSIONS. During disease progression in the prostate, production of TSP-1, the major inhibitor, is down-regulated while that of stimulatory FGF-2 and/or VEGF rise, leading to the induction of the new vessels necessary to support tumor growth. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:293 / 305
页数:13
相关论文
共 75 条
[61]   CATHEPSIN-B IN ANGIOGENESIS OF HUMAN PROSTATE - AN IMMUNOHISTOCHEMICAL AND IMMUNOELECTRON MICROSCOPIC ANALYSIS [J].
SINHA, AA ;
GLEASON, DF ;
STALEY, NA ;
WILSON, MJ ;
SAMENI, M ;
SLOANE, BF .
ANATOMICAL RECORD, 1995, 241 (03) :353-362
[62]   Changes in growth factor expression in the ageing prostate may disrupt epithelial-stromal homeostasis [J].
Slater, M ;
Barden, JA ;
Murphy, CR .
HISTOCHEMICAL JOURNAL, 2000, 32 (06) :357-364
[63]   Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts [J].
Stewart, RJ ;
Panigrahy, D ;
Flynn, E ;
Folkman, J .
JOURNAL OF UROLOGY, 2001, 165 (02) :688-693
[64]  
Strohmeyer D, 2000, PROSTATE, V42, P26
[65]   Extracellular matrix-associated transforming growth factor-β:: Role in cancer cell growth and invasion [J].
Taipale, J ;
Saharinen, J ;
Keski-Oja, J .
ADVANCES IN CANCER RESEARCH, VOL 75, 1998, 75 :87-134
[66]   PEPTIDES DERIVED FROM 2 SEPARATE DOMAINS OF THE MATRIX PROTEIN THROMBOSPONDIN-1 HAVE ANTI-ANGIOGENIC ACTIVITY [J].
TOLSMA, SS ;
VOLPERT, OV ;
GOOD, DJ ;
FRAZIER, WA ;
POLVERINI, PJ ;
BOUCK, N .
JOURNAL OF CELL BIOLOGY, 1993, 122 (02) :497-511
[67]   ASSOCIATION OF TRANSFORMING GROWTH FACTOR-BETA-1 WITH PROSTATE-CANCER - AN IMMUNOHISTOCHEMICAL STUDY [J].
TRUONG, LD ;
KADMON, D ;
MCCUNE, BK ;
FLANDERS, KC ;
SCARDINO, PT ;
THOMPSON, TC .
HUMAN PATHOLOGY, 1993, 24 (01) :4-9
[68]   A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1 [J].
Volpert, OV ;
Lawler, J ;
Bouck, NP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6343-6348
[69]   Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity [J].
Volpert, OV ;
Dameron, KM ;
Bouck, N .
ONCOGENE, 1997, 14 (12) :1495-1502
[70]   INFLUENCE OF TUMOR SIZE ON HUMAN-PROSTATE TUMOR-METASTASIS IN ATHYMIC NUDE-MICE [J].
WARE, JL ;
DELONG, ER .
BRITISH JOURNAL OF CANCER, 1985, 51 (03) :419-423